Sangamo Therapeutics (SGMO) Return on Equity (2016 - 2025)
Historic Return on Equity for Sangamo Therapeutics (SGMO) over the last 15 years, with Q3 2025 value amounting to 8.43%.
- Sangamo Therapeutics' Return on Equity fell 41400.0% to 8.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.43%, marking a year-over-year decrease of 41400.0%. This contributed to the annual value of 1.85% for FY2024, which is 4900.0% down from last year.
- As of Q3 2025, Sangamo Therapeutics' Return on Equity stood at 8.43%, which was down 41400.0% from 5.17% recorded in Q2 2025.
- Sangamo Therapeutics' Return on Equity's 5-year high stood at 0.26% during Q1 2021, with a 5-year trough of 8.43% in Q3 2025.
- For the 5-year period, Sangamo Therapeutics' Return on Equity averaged around 2.43%, with its median value being 0.7% (2023).
- Per our database at Business Quant, Sangamo Therapeutics' Return on Equity plummeted by -55100bps in 2024 and then surged by 10500bps in 2025.
- Sangamo Therapeutics' Return on Equity (Quarter) stood at 0.46% in 2021, then plummeted by -40bps to 0.64% in 2022, then plummeted by -272bps to 2.37% in 2023, then tumbled by -34bps to 3.16% in 2024, then crashed by -166bps to 8.43% in 2025.
- Its Return on Equity stands at 8.43% for Q3 2025, versus 5.17% for Q2 2025 and 5.74% for Q1 2025.